Annuncio • Dec 12

Pharma Two B Ltd. cancelled the acquisition of Hepion Pharmaceuticals, Inc. (NasdaqCM:HEPA) from Armistice Capital Master Fund Ltd., fund managed by Armistice Capital LLC and others in a reverse merger transaction.

Pharma Two B Ltd. executed a Letter of Intent to acquire Hepion Pharmaceuticals, Inc. (NasdaqCM:HEPA) from Armistice Capital Master Fund Ltd., fund managed by Armistice Capital LLC and others in a reverse merger transaction valued at an implied equity value of approximately $58.5 million on April 1, 2024. Pharma Two B Ltd. agreed to acquire Hepion Pharmaceuticals, Inc. (NasdaqCM:HEPA) from Armistice Capital Master Fund Ltd., fund managed by Armistice Capital LLC and others in a reverse merger transaction on July 19, 2024. In support of the Merger, Pharma Two B has entered into a securities purchase agreement for an $11.5 million private placement of ordinary shares and accompanying Series A warrants and Series B warrants with a syndicate of new and existing institutional life science investors. The transaction is subject to approval of merger agreement by target board, approval of offer by acquirer shareholders, approval of offer by target shareholders and registration statement effectiveness. The deal has been unanimously approved by the board of both companies. The Registration Statement became effective on November 11, 2024. The expected completion of the transaction is the fourth quarter of 2024. As of October 15, 2024, the board of directors of Hepion Pharmaceuticals, Inc. has approved the Agreement and Plan of Merger. The closing of the Merger is conditioned on approval of the Merger Proposal by stockholders. A Special Meeting of Stockholders of Hepion Pharmaceuticals will be held on December 12, 2024. A.G.P./Alliance Global Partners is serving as financial advisor to Hepion and Jeffrey Fessler, Lindsay Ferguson, Dmitriy Chelnitsky, Dominick DiSabatino, Eric Raphan and Niya Tang, Malika Levarlet of Sheppard, Mullin, Richter & Hampton LLP is acting as U.S. legal advisors to Hepion and Lipa Meir & Co.is acting as Israeli legal advisor to Hepion. Sullivan & Worcester LLP is serving as legal advisor to A.G.P. Laidlaw & Company (UK) Ltd. is acting as financial advisor to Pharma Two B. and Mike Rimon and Matthew Rudolph of Meitar Law Offices and Mayan Katz and Marianne C. Sarrazin of Goodwin Procter LLP are acting as legal advisors to Pharma Two B. Hepion has hired Campaign Management to assist in the proxy solicitation process. Hepion will pay Campaign Management a fee of $13,000, plus disbursements. Pacific Stock Transfer Company is Transfer Agent for Hepion Pharmaceuticals. ValueScope, Inc. provided fairness opinion to the board of Hepion Pharmaceuticals against a fee of $85,000. Vstock Transfer, LLC acted as transfer agent to Pharma Two B Ltd. ValueScope, Inc. acted as financial advisor to Hepion Pharmaceuticals, Inc. Pharma Two B Ltd. cancelled the acquisition of Hepion Pharmaceuticals, Inc. (NasdaqCM:HEPA) from Armistice Capital Master Fund Ltd., fund managed by Armistice Capital LLC and others in a reverse merger transaction on December 10, 2024. Neither party will be required to pay the other a termination fee as a result of the mutual decision to terminate the agreement. Hepion also announced that its previously announced special meeting of its stockholders scheduled for December 12, 2024 has been cancelled.

Annuncio • May 23

Hepion Pharmaceuticals, Inc. Announces Positive Topline Results from Its Recently Completed Phase 2 Altitude-Nash Clinical Trial

Hepion Pharmaceuticals, Inc. announced positive topline results from its recently completed Phase 2ALTITUDE-NASH clinical trial. ALTITUDE-NASH met its primary endpoint by demonstrating improved physiologic liver function and was well tolerated after four months of treatment in subjects with stage 3 or greater fibrosis based on the AGILE 3+ criteria. All additional secondary endpoints were also met, including reductions in the liver injury biomarkers, alanine and aspartate transaminases; and multiple fibrosis-associated biomarkers, including ProC3 (procollagen 3 C-terminal peptide), PIIINP (procollagen 3 N-terminal peptide), TIMP1 (tissue inhibitor of metalloproteinase-1), hyaluronic acid, and enhanced liver fibrosis (ELF) scores (composite of PIIINP, TIMP1, and hyaluronic acid). These observations build on similar findings from a shorter Phase 2a trial and reinforce rencofilstat’s direct antifibrotic mode of action and increase the confidence for reductions in fibrosis in Hepion’s ongoing Phase 2b ASCEND-NASH paired biopsy trial. Primary Endpoint: Four Measures of Liver Impairment Significantly Improved Compared to Baseline with Four Months Rencofilstat 225 mg Treatment: The HepQuant SHUNT Test was used in this study under an U.S. Food and Drug Administration (“FDA”)-issued Investigational Device Exemption (IDE). The SHUNT Test is a minimally invasive test that tracks changes in the degree of liver function impairment and was used to determine four key measures: HepQuant DSI™ (Disease Severity Index) score, which primarily reflects hepatocyte function; SHUNT, which reflects the impact of micro-architectural changes, such as fibrosis on blood flow through the liver; HepQuant HR™ (Hepatic Reserve); and RISK ACE, which reflects the annual risk of a patient developing an adverse clinical outcome. Rencofilstat met the primary endpoint and lowered mean DSI score in all doses, with rencofilstat 225 mg treatment over 4 months resulting in statistically significant decreases in DSI (mean ? = -1.62 units; p<0.05), SHUNT% (mean ? = -2.8%; p<0.05), HR% (mean ? = 3.9%; p<0.01), and RISK ACE (mean ? = -1.2 events per 100 patient-years; p<0.001) compared to baseline; and 61% of subjects in the 225 mg rencofilstat arm had a DSI improvement of >2.0 points (p<0.05). In HepQuant’s research, improvements from baseline, especially for high DSI scores that decrease by 2.0 points or more, are associated with clinically significant reductions in risk for liver related complications, including esophageal varices and encephalopathy. To address the potential of rencofilstat for patients with the most advanced functional impairment and greatest risk of disease progression, an analysis was conducted on the 34 subjects with DSI>17 or SHUNT%>25 as research indicates these subjects are at high risk for hepatic complications (Table 2). In this subgroup, independent of rencofilstat dose, statistically significant decreases at Day 120 compared to baseline were again observed for DSI score (mean ? = -1.30 units; p<0.05), SHUNT% (mean ? = -3.4%; p<0.01), HR% (mean ? = 2.9%; p<0.05), and RISK ACE (mean ? = -1.6 events per 100 patient-years; p<0.01). The large reduction in SHUNT% suggests alleviation of micro-architectural defects as anticipated from an antifibrotic agent and suggests that rencofilstat may be most effective in patients with more severe liver impairment. Multiple biomarkers related to fibrosis were improved following four months of treatment with rencofilstat: ProC3, PIIINP, TIMP1, and hyaluronic acid. ELF scores were similarly improved by rencofilstat. Robust reductions in ALT and AST were also observed with all doses of rencofilstat, with the greatest reductions seen in the 225 mg rencofilstat dosing arm. Incremental dose-response patterns were observed for most of the biomarkers, and in all cases the largest reductions from baseline for each of the biomarkers occurred in the 225 mg rencofilstat group. Additional analyses were performed on the approximate one-third of subjects with elevated baseline ProC3, which assesses the formation of type III collagen and indicates both severity and activity of disease. Because Pro-C3 is a measure of collagen cleavage during active fibrinogenesis, subjects with high ProC3 levels represent a NASH population with more active disease, therefore representing an important target population for many NASH drug candidates. In ALTITUDE-NASH, the greatest magnitude of effects was observed with 225 mg rencofilstat (Table 4), and most frequent dose-dependencies were observed in subjects with baseline ProC3>37.5 ng/ml (Roche, Elecsys). Rencofilstat 225 mg, and often the 150 mg dose, led to greater improvements than with 75 mg rencofilstat for all the NASH biomarkers in this high-risk population as well as in the entire study population. Primary Safety and Tolerability Endpoints Met with No Serious Adverse Events Attributed to Rencofilstat: Of the 70 subjects enrolled in the study, 67 completed all study procedures including 120 days oral dosing of rencofilstat with a 14-day routine safety follow up period. Rencofilstat was well tolerated, with no trends in adverse events or safety signals identified. There were no deaths or hepatic decompensation events recorded in the trial, and a total of five serious adverse events (SAEs) occurred with four unrelated to study drug (COVID-19, headache, fibula fracture, COPD) and a single SAE (biliary acute pancreatitis) classified as possibly related to study drug in a subject diagnosed with a pancreatic stone as the likely source for the pancreatitis. Other safety labs, EKGs, and physical exams did not reveal any safety signals or concerns over the course of the study. Study Design and Objectives: ALTITUDE-NASH was designed as a Phase 2, multi-center, randomized, open label study. F3 NASH subjects were identified by having a baseline AGILE 3+ screening score of =0.53 or historical biopsy obtained within the preceding 6 months. The AGILE 3+ score is calculated using FibroScan fibrosis score, laboratory values (AST, ALT, platelets), and clinical parameters (age, sex, diabetes status). Subjects were randomized to one of three rencofilstat treatment groups receiving either 75 mg, 150 mg, or 225 mg soft gelatin capsules once daily for a period of 4 months. The HepQuant Shunt test was administered at baseline, Day 60, and Day 120 of treatment in addition to serum analyses for safety and efficacy markers at each study visit. End-of-study liver biopsies or other measures of structural extracellular matrix changes were not collected due to the relatively short duration of treatment.

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	4.3%
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	2.9yrs

Nome	Posizione	Mandato	Compensazione	Proprietà
Vincent LoPriore	Executive Chairman	less than a year	Nessun dato	4.29% $ 194.2k
Gary Stetz	Interim CEO & Director	less than a year	Nessun dato	4.29% $ 194.2k
Vlad Ratziu	Member of Scientific Advisory Board	3.4yrs	Nessun dato	Nessun dato
Rohit Loomba	Member of Scientific Advisory Board	3.4yrs	Nessun dato	Nessun dato
Stephen A. Harrison	Scientific Advisory Board Chair	7yrs	Nessun dato	Nessun dato
Nikolai Naoumov	Member of Scientific Advisory Board	3.4yrs	Nessun dato	Nessun dato
Sireesh Appajosyula	Independent Director	less than a year	Nessun dato	4.29% $ 194.2k
Philippe Gallay	Member of Scientific Advisory Board	10.1yrs	Nessun dato	Nessun dato
Michael Purcell	Independent Director	2.4yrs	US$74.25k	4.29% $ 194.2k
Yury Popov	Member of Scientific Advisory Board	3.4yrs	Nessun dato	Nessun dato
Chase LoPriore	Independent Director	less than a year	Nessun dato	4.29% $ 194.2k
Gary Stetz	Director	less than a year	Nessun dato	Nessun dato

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2026/08/13 00:38
Prezzo dell'azione a fine giornata	2026/08/13 00:00
Utili	2026/03/31
Utili annuali	2025/12/31

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

Analista	Istituzione
James Molloy	Alliance Global Partners
Kumaraguru Raja	Brookline Capital Markets
Kristen Kluska	Cantor Fitzgerald & Co.

Hepion Pharmaceuticals Gestione

Criteri Gestione verificati 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Hepion Pharmaceuticals, Inc. Approves Board Appointments, Effective July 1, 2026

Hepion Pharmaceuticals, Inc., Annual General Meeting, Jun 17, 2026

Hepion Pharmaceuticals, Inc. Announces Resignation of John Brancaccio as Chief Financial Officer, Effective June 30, 2025

Hepion Pharmaceuticals, Inc Announces CEO Changes

Hepion Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2025

High number of new and inexperienced directors

Recent updates

Hepion Pharmaceuticals, Inc. Approves Board Appointments, Effective July 1, 2026

Hepion Pharmaceuticals, Inc., Annual General Meeting, Jun 17, 2026

Hepion Pharmaceuticals, Inc. announced that it has received $0.7 million in funding

The Nasdaq Stock Market to Delist the Common Stock of Hepion Pharmaceuticals

Hepion Pharmaceuticals, Inc. Announces Resignation of John Brancaccio as Chief Financial Officer, Effective June 30, 2025

Hepion Pharmaceuticals, Inc Announces CEO Changes

Hepion Pharmaceuticals, Inc. announced delayed 10-Q filing

Hepion Pharmaceuticals, Inc.(OTCPK:HEPA) dropped from S&P TMI Index

Hepion Pharmaceuticals, Inc.(OTCPK:HEPA) dropped from NASDAQ Composite Index

Hepion Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2025

Hepion Pharmaceuticals Receives Written Notice from Nasdaq Due to Public Shell Status

Hepion Pharmaceuticals, Inc. announced delayed annual 10-K filing

Hepion Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Minimum Bid Price Requirement

High number of new and inexperienced directors

Hepion Pharmaceuticals, Inc., Annual General Meeting, Mar 10, 2025

Hepion Pharmaceuticals Receives Written Notice from the Nasdaq Stock Market

Hepion Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

Pharma Two B Ltd. cancelled the acquisition of Hepion Pharmaceuticals, Inc. (NasdaqCM:HEPA) from Armistice Capital Master Fund Ltd., fund managed by Armistice Capital LLC and others in a reverse merger transaction.

New major risk - Shareholder dilution

Hepion Pharmaceuticals Receives Non-Compliance Letter from Nasdaq Regarding Stockholder's Deficit

New major risk - Financial position

Hepion Pharmaceuticals Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(a)(2)

High number of new and inexperienced directors

Pharma Two B Ltd. agreed to acquire Hepion Pharmaceuticals, Inc. (NasdaqCM:HEPA) in a reverse merger transaction valued at an implied equity value of approximately $58.5 million.

Hepion Pharmaceuticals, Inc. announced delayed 10-Q filing

Hepion Pharmaceuticals, Inc. Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial

Hepion Pharmaceuticals, Inc. announced delayed annual 10-K filing

Hepion Pharmaceuticals, Inc. Appoints Michael Purcell to Its Board of Directors

New major risk - Share price stability

Price target decreased by 27% to US$30.00

High number of new and inexperienced directors

Hepion Pharmaceuticals, Inc. Announces Resignation of Anand Reddi from the Board of Directors

Hepion Pharmaceuticals, Inc. Announces Resignation of Robert Foster as Director

Hepion Pharmaceuticals, Inc. announced delayed 10-Q filing

Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-Week Phase 2 Study of Advanced (F3) Mash Liver Disease

New minor risk - Share price stability

Hepion Pharmaceuticals, Inc. Announces the Publication of New Research Study in Mice

New minor risk - Shareholder dilution

Hepion Pharmaceuticals, Inc. announced that it has received $5.000004 million in funding

Price target decreased by 46% to US$23.67

Hepion Pharmaceuticals, Inc. Announces Results from A Study with in Which the Anti-Cancer Activity of Hepion's Lead Drug Candidate, Rencofilstat

Hepion Pharmaceuticals, Inc. Announces Positive Results from Translational Research Study

Hepion Pharmaceuticals, Inc. Announces Resignation of Dr. Todd Hobbs, as the Chief Medical Officer, Effective September 29, 2023

New major risk - Financial position

Hepion Pharmaceuticals (NASDAQ:HEPA) Will Have To Spend Its Cash Wisely

New major risk - Financial position

Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial of Rencofilstat

Hepion Pharmaceuticals, Inc. Announces Positive Topline Results from Its Recently Completed Phase 2 Altitude-Nash Clinical Trial

Price target decreased by 10% to US$62.67

High number of new directors

We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate

Hepion Pharmaceuticals, Inc. Announces Positive Results of Preclinical Studies Examining Rencofilstat as A Potential Therapeutic for Multiple Myeloma

Hepion Pharmaceuticals, Inc. Presents of Preclinical Study Highlighting Anti-Cancer Activity of Rencofilstat in Combination with Proteosome Inhibitors

Price target decreased to US$2.50

We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate

Hepion Pharma rises as company begins NASH treatment trial

Will Hepion Pharmaceuticals (NASDAQ:HEPA) Spend Its Cash Wisely?

Price target decreased to US$4.75

Hepion Pharmaceuticals CEO Robert Foster - Dash To Beat NASH

Hepion Pharmaceuticals: Facing The Momentous Year 2022

Additional Phase IIa Data Confirms Hepion's CRV431 As A Very Promising NASH Candidate Drug

Companies Like Hepion Pharmaceuticals (NASDAQ:HEPA) Are In A Position To Invest In Growth

Hepion Pharmaceuticals: A Promising Early-Stage Biopharma In The NASH Race

What Type Of Shareholders Make Up Hepion Pharmaceuticals, Inc.'s (NASDAQ:HEPA) Share Registry?

New 90-day high: US$2.98

AMMINISTRATORE DELEGATO

Membri del Consiglio di amministrazione

Analisi aziendale e situazione dei dati finanziari

Fonti dei dati